Market.us has recently published a market research report titled, “Global Deferiprone Market by Formulation, and by Indication – Forecast from 2019 to 2028”. The report offers a detailed analysis of the deferiprone market. It is through systematic and exhaustive research efforts, both primary and secondary, that the research results have been thoroughly examined over the study period. The global deferiprone market is projected to be valued at over US$ 237.8 million, from its estimated revenue of US$ 34.7 million generated in 2018.
Deferiprone is a drug that chelates iron in an individual’s bloodstream. It is used to treat individuals suffering from thalassemia major, where there is an overload of iron in a patient’s system. Another condition deferiprone is used for is the treatment of patients that have a lack of iron excretion mechanisms in their blood. This condition can lead to a build-up of toxic substances which will ultimately cause premature iron-induced death. It is also used in the treatment of other conditions such as neutropenia, agranulocytosis, etc.
The steady rise in the number of life-threatening diseases such as thalassemia being diagnosed and treated for is subsequently increasing the demand for chelating agents. As a result, the revenue growth of the global deferiprone market is projected to expand in the coming years. Another factor that is projected to play a pivotal role in the revenue growth of the global deferiprone market is the anticipated increase in demand from emerging economies. This can be owed to the better facilitation and provision of these drugs to individuals that require them.
Unfortunately, this drug is only prescribed to patients when chelation therapy seems inadequate. This is because deferiprone is considered to be carcinogenic, teratogenic and genotoxic. The various side effects of deferiprone are nausea, diarrhea, vomiting, joint pain, hypersensitivity, zinc deficiency, headaches, back pain, etc; this could potentially restrain market growth in the foreseeable future.
However, increased investment towards R&D by major market players is expected to lead to better innovations which in turn, will increase the adoption of this drug and subsequently boost market revenue growth in the foreseeable future.
In terms of formulation market segmentation – oral solution, tablet, and capsules. The tablet segment accounted for the majority revenue share of the market, although, the oral solution segment is expected to register the highest revenue growth in the years to come.
Indication segmentation of the market is as follows – transfusional iron overload and NTDT caused iron overload segments. The transfusional iron overload segment accounted for the majority revenue share of the market.
The global deferiprone market research report includes company profiles of major players/companies such as Сірlа Lіmіtеd, Ароtех Іnс., Ѕwеdіѕh Оrрhаn Віоvіtrum АВ (рubl), Gеnерhаrm Ѕ.А., Lіроmеd АG, Аmbrоѕіа Rеmеdіеѕ (Р) Ltd., Fосuѕ Рhаrmасеutісаlѕ Lіmіtеd, etc.
“Global Deferiprone Market Report 2019: Industry Analysis, Business Growth, Drivers, Restraints, Manufactures, Trends, Applications, Leading Companies, and Growth Forecast 2018 – 2028” report has been prepared based on in-depth market analysis with inputs from industry experts. This report covers the present landscape and future growth prospects of the global deferiprone market for 2019–2029.